
Phase III trial suggests meropenem–vaborbactam a valuable option for CRE infection
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.